版本:
中国

BRIEF-Epizyme earns $6 million from Glaxosmithkline for initiation of clinical development

Sept 15 Epizyme Inc :

* Earns $6 million milestone payment from Glaxosmithkline for initiation of clinical development with first in-class PRMT5 inhibitor

* Says milestone payment follows GSK's initiation of patient dosing in a Phase 1 clinical trial of GSK3326595

* GSK initiated Phase 1, dose-escalation study to investigate safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK3326595 Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐